<?xml version="1.0" encoding="UTF-8"?>
<ref id="R50">
 <label>50.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Byrd</surname>
    <given-names>JC</given-names>
   </name>
   <name>
    <surname>Furman</surname>
    <given-names>RR</given-names>
   </name>
   <name>
    <surname>Coutre</surname>
    <given-names>SE</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: Final analysis of the pivotal phase 1b/2 PCYC-1102 study</article-title>. 
  <source>
   <italic toggle="yes">Clin Cancer Res.</italic>
  </source>
  <year>2020</year>;
  <comment>March 24. [Epub ahead of print]</comment>.
 </mixed-citation>
</ref>
